^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Excerpt:
Patients were either pre-screened for alterations in FGFR3, or underwent genomic assessment identifying these alterations in the course of routine clinical care….FGFR3 mutations permitted in the study included mutations in exon 7 (R248C, S249C), exon 10 (G372C, A393E, Y375C), or exon 15 (K652M/T, K652E/Q). FGFR3 gene fusions were permitted, including but not limited to FGFR3–TACC3 fusion....BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease.
DOI:
10.1158/2159-8290.CD-18-0229
Source:
Title:
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterationsl Cancers with FGFR3 Alterations
Published date:
05/01/2020
Excerpt:
In this study, we demonstrate that cells expressing cancer-associated activating FGFR3 mutants and the FGFR3-TACC3 fusion showed primary resistance to infigratinib in long-term colony formation assays in both NIH-3T3 and urothelial carcinoma models.
DOI:
10.3390/ijms21093214
